GENE ONLINE|News &
Opinion
Blog

Hemophilia A
FDA Approves Sanofi and Sobi’s Once-Weekly Hemophilia A Med
2023-02-23
Pfizer, Sangamo Re-Opens Enrolment For Hemophilia A Gene Therapy
2022-09-26
Sanofi’s Treatment for Hemophilia A has a Concrete FDA Decision Date
2022-08-30
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
Pfizer, Sangamo Dose First Hemophilia A Patient in Phase 3 with Gene Therapy Candidate
2020-10-08
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
Sangamo’s Shares Goes up after the Announcement of Investigational Hemophilia A Gene Therapy Results
2019-07-19
Emicizumab promises weekly/biweekly prophylaxis in hemophilia-A patients
2018-09-04
LATEST
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
2024-07-23
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
EVENT
Scroll to Top